Implementing AI in Life Sciences: A Phased Approach for Sustainable Transformation
Introduction to AI in Enterprise Strategy
Artificial Intelligence (AI) and its subset, generative AI, are increasingly becoming foundational elements of enterprise strategy, particularly in industries such as life sciences. By 2025, enterprise AI adoption is projected to reach unprecedented levels, with over 80% of companies either incorporating or exploring AI solutions. However, while many organizations recognize the potential of AI, only a small percentage are achieving substantial results. A common challenge is the phenomenon known as “death by a thousand pilots,” where organizations pursue numerous small-scale AI projects without a cohesive strategy, ultimately failing to drive meaningful change.
To truly realize the transformative potential of AI, organizations must adopt a holistic, AI-led digital strategy. This involves top-down, phased implementation plans complemented by Strategic Workforce Planning (WSP) to capture and sustain value from AI transformations. This article outlines potential approaches for phased implementation, using clinical trials as a case study.
The Digital Clinical Maturity Assessment (DCTMa) Framework
A valuable tool in this endeavor is the Digital Clinical Maturity Assessment (DCTMa) framework. This comprehensive framework consists of 10 core parameters for successful AI transformation, enabling organizations to benchmark their current maturity against industry peers, identify gaps, and develop a targeted AI-led digital transformation strategy.
By assessing their “current score” on these parameters, organizations can systematically plan their transformation journey, ensuring alignment and effectiveness in their AI initiatives.
Phased Implementation of AI Transformation
AI-based transformations necessitate a multifaceted strategy that addresses various components to achieve most transformation objectives. A balanced scorecard (BSC) can provide a structured approach for developing Key Performance Indicators (KPIs) across four categories:
-
Market Positioning and Customer Experience: Enhancing customer satisfaction and loyalty.
- KPIs: AI-impacted Net Promoter Score (NPS), Customer Lifetime Value (CLV) uplift, and impacts of digital clinical trials (DCTs) on product launch timelines.
-
Financial Performance/Value Creation: Evaluating return on AI investments (ROAI).
- KPIs: Net financial gains from AI investments, digital revenue contributions, and revenue increases due to swift market entry via AI-driven DCTs.
-
Organizational Capability/Innovation: Developing staff skills and adoption of AI tools.
- KPIs: Time-to-market for new AI features, percentage of AI models audited for bias, and employee engagement with AI processes.
-
Operational Excellence/Productivity: Streamlining processes and ensuring effective monitoring.
- KPIs: Reduction in process cycle times, automation of high-value tasks, and accuracy measures for AI models.
Establishing a phased implementation plan enables life sciences companies to develop initiatives, set timelines, and define KPIs to track success. This plan should clarify roles and responsibilities, minimize risks, secure stakeholder buy-in, and maximize long-term benefits.
Phase 1: Establishing Foundational AI and Robotic Process Automation (RPA)
Definition/Scope
Phase 1 focuses on implementing basic AI technologies such as RPA, workflow automation, and basic integration platforms.
Capabilities and Tools
These technologies typically involve task execution without cognition and structured outputs based on rule-following. Platforms like UiPath, Zapier, and Power Automate are central to this phase.
Examples
Practical applications include pre-scheduling patient visits and automating data transfers between systems.
Estimated Benefits
Organizations can expect time savings of 20%–40% and cost savings of 15%–30% from these foundational efforts.
Key Activities:
- Establishing data governance and infrastructure
- Implementing RPA
- Initiating Level 1 conversational AI and basic predictive analytics
- Conducting performance tracking aligned with strategic goals
Expected Outcomes:
- Reduced costs and increased operational efficiency.
Phase 2: Adding Autonomous AI and Intelligent Process Automation (IPA)
Definition/Scope
This phase incorporates advanced AI technologies such as large language models (LLMs) for content creation and summarization.
Capabilities and Tools
Technologies include tools that can understand natural language and generate insights from unstructured data. Resources like ChatGPT and Claude are utilized.
Examples
Tasks might involve drafting clinical study reports or summarizing patient adverse event narratives.
Estimated Benefits
Companies can achieve 40%–70% reductions in knowledge task efforts and significant boosts in productivity.
Key Activities:
- Implementing advanced predictive analytics
- Developing personalized user experiences
- Leveraging AI-assisted design processes
Expected Outcomes:
- Enhanced decision-making and customer satisfaction as AI provides real-time insights.
Phase 3: Embracing Agentic AI and Holistic Transformation Initiatives
Definition/Scope
This phase focuses on highly autonomous AI agents capable of planning, reasoning, and executing multistep tasks.
Capabilities and Tools
Technologies include frameworks for agent-based management, enabling feedback-based learning and memory.
Examples
Applications range from autonomous trial monitoring agents to self-optimizing systems that adapt to changes.
Estimated Benefits
Operational throughput can improve five to ten times, with complex workflows achieving up to 90% automation.
Key Activities:
- Implementing agentic AI pilots
- Establishing ethical guidelines for AI usage
- Integrating new business models across the enterprise
Expected Outcomes:
- Transformations that lead to new revenue streams and significant operational efficiencies.
Key Benefits of a Phased AI Strategy
1. Validation of AI-Driven Strategy
A phased approach allows organizations to validate business models with market feedback, ensuring alignment with strategic objectives at each phase.
2. Stakeholder Buy-In and Change Management
Gradually implementing changes allows for smoother transitions, fostering employee adoption and demonstrating value early on.
3. Efficient Resource Allocation
Phased implementation spreads financial and operational resource allocation over time, reducing risk and preventing bottlenecks.
4. Continuous Learning and Improvement
An iterative approach enables organizations to adapt based on feedback, fostering agility and continuous enhancement.
5. Proactive Risk Mitigation
Breaking down the implementation into manageable phases helps identify and address challenges early, minimizing disruption.
Conclusion
Life sciences organizations are encouraged to navigate the complexities of AI implementation through a holistic, phased strategy. By documenting desired outcomes, defining metrics such as KPIs, and facilitating communication across the organization, they can pave the way for successful transformation. It’s imperative to prioritize integrated strategic workforce planning for the overall success of AI initiatives.
About the Author
Krishnan Rajagopalan, Ph.D., is the president of Life Sciences – Sourcing Advisory and Consultancy Services. With 30 years of experience in management consulting and advisory roles, he specializes in guiding life sciences companies through growth strategies and operational transformations. You can connect with him on LinkedIn or reach him at +1 908 380 3343.
